Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Applied Therapeutics Inc. (APLT) (i.) hat eine Fast Track-Zulassung auf AT-007 zur Behandlung von Galaktosämie, einer seltenen Stoffwechselerkrankung erhalten. AT-007 ist der in das Zentralnervensystem eindringende Aldose-Reduktase-Inhibitor des Unternehmens in der Entwicklung für mehrere seltene Stoffwechselerkrankungen, darunter Galaktosämie, SORD und PMM2-CDG. Diese Nachricht könnte ein wichtiger...
Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Therapeutics, Inc. investors that lost money are encouraged to contact BFA Law before February 18, 2025 class action deadline.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been...
NEW YORK, Feb. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ:...
